Pharma industry expects to report 7-9 pc revenue growth in FY23

Rating agency CRISIL attributed headwinds in export sales in the regulated markets and the high-base effect in the domestic formulations business as the major reason for moderate revenue growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7NiwsRx
via IFTTT